Featured Stocks

Youngevity International, Inc. (NASDAQ: YGYI)

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Investment Considerations

  • Annual revenue growth from $75 million in 2012 to $166 million in 2017
  • YGYI selected by NASDAQ as Fit Week Company in January 2018; added to Russell Index in June 2018
  • Youngevity’s strong presence in large, scalable, top global vertical market segments includes the $216 billion anti-aging sector, $154 billion skin care space, $11.6 billion brain health market, and $241 billion weight loss industry
  • International expansion well underway with corporate infrastructure, product approvals, newly acquired distributors and customers now driving revenue
  • CLR Roaster has entered into a 5-year contract with a major coffee important and exporter for the sale and processing of over 41 million pounds of green coffee on an annual basis. Contract is estimated to generate revenues of $250 million from 2019 through 2023, with first shipments beginning January 2019.


Wednesday, August 22nd, 2018 Featured Stocks Comments Off

VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQB: VVCIF)

VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQB: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

Investment Considerations

  • Rapidly growing global medical cannabis industry expected to reach $55 billion in sales by 2025, with analysts projecting Canada’s medicinal cannabis market will reach $1 billion by 2020
  • VIVO’s ability to expand cannabis production dramatically is secured with 65 acres ready for development
  • One of earliest licensed medical cannabis producers in Canada; recently received license to produce medicinal cannabis oils
  • Highly experienced management team, board of directors and advisors
  • Global initiatives underway to expand to Europe, Australia and Israel


Tuesday, August 7th, 2018 Featured Stocks Comments Off

TransCanna Holdings Inc. (CSE: TCAN)

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

Investment Considerations

  • Creating a distribution network throughout California to serve the state’s $8.6 billion cannabis industry
  • Plans include construction of 10,000-square-foot distribution and transportation facility in Adelanto, California, with plans for several more in strategic locations around the state
  • Holds transportation and distribution permit from Adelanto municipal government
  • Has access to Track & Trace software platform, a requirement of California’s Bureau of Cannabis Control


Tuesday, August 7th, 2018 Featured Stocks Comments Off

Pressure BioSciences Inc. (PBIO)

Pressure BioSciences, Inc. develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Investment Considerations

  • Poised to disrupt sciences sample preparation market estimated at $6 billion
  • Nearly 300 patented enabling technology platform products installed at more than 150 sites worldwide
  • Two patents awarded in China for Ultra Shear Technology used in wide range of industrial applications, including “clean foods.”
  • Finalist in prestigious 2017 R&D 100 Awards recognizing top revolutionary technologies.
  • Technology being used as part of the U.S. “Cancer Moonshot” initiative.


Monday, October 2nd, 2017 Featured Stocks Comments Off

Pacific Software, Inc. (PFSF)

Pacific Software, Inc. (OTC: PFSF) is an emerging technology corporation positioned for investments, mergers and acquisitions of software technologies and platforms. The company is building “BoaPin,” a subscription-based e-commerce trading platform focused on cross border trade expansion with an international emphasis. The multi-faceted e-commerce platform is scheduled for launch in Q1 of 2019.

The Company is uniquely positioned to deliver a B2B and B2C intelligent e-commerce trade platform which will provide various solutions, data, applications and tools for subscribers, including IBM’s Hyperledger Blockchain “Backend as a Service” (BaaS) Infrastructure, multi-lingual communication, fintech, digital marketing, smart contracts, commodities search/match applications, customs clearance, taxation data, product advertising and logistics solutions.

Through smart contract technology for global supply chain management, BoaPin is designed to improve product traceability and deliver solutions to its subscribers for product certification, marketing, logistics, commodities search/match interface, trade finance, cross border payment solutions and customs clearance. Some of the tools available to execute these capabilities include cross border payments, blockchain solutions, smart contracts and multilingual access.

With these features at hand, the company is targeting several key industries where its online applications and solutions could have significant corporate impact in various forms, including: agriculture, fertilizers, chemicals, cosmetics, electronics, equipment, apparel and controlled substance management.

Business Model

Pacific Software initially will focus on Brazil and China for BoaPin. After paying a registration fee to utilize the online trade portal, subscribers to the platform will have access to a variety of tools and features that may enhance and increase revenue initiatives by showcasing their commodities and products for sale or trade.

Buyers of the commodities, products or services will pay a transaction fee only to the company which could materialize in the form of cash, cash equivalents, royalties or in-kind fees.

As the company executes its strategy, the online trade business is anticipated to generate significant revenue from subscribers obtained from regionally and federally organized Brazilian Trade Associations. The members wish to market their commodities or products, and the portal users or buyers materialize from China, Hong Kong and surrounding countries. As a result, this business model may be organized separately in the company’s wholly owned subsidiary, incorporated as HyperSoft Ventures, which could generate appreciable value for investors and shareholders.

Investment Considerations

  • Designing and powering the BoaPin e-commerce, cross border commodities trading platform creating solutions for sectors highly reliant on supply chain transparency, accountability and efficiency for buyers
  • Business model allows for the formation of a wholly owned subsidiary incorporated as HyperSoft Ventures
  • Working relationship with IBM provides expertise on supply chain implementations, blockchain technology and applications
  • Management has more than 50 years of combined experience in finance, M&A and investments
  • Advisory team led by Dr. Wang-Chan Wong, a 25-year veteran of global IT enterprise
Tuesday, May 9th, 2017 Featured Stocks Comments Off

Net Element (NASDAQ: NETE)

Net Element, Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

In a partnership with Bunker Capital, Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jonathan New, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Investment Considerations

  • One-stop omni-channel processing solution with 100-plus payment solutions
  • North American transaction revenues rose by 17.3% YoY
  • Organic growth includes increase in global merchants and uptake of value-added services
  • Ranked as one of North America’s fastest growing companies on Deloitte’s 2017 Technology Fast 500™


Tuesday, May 9th, 2017 Featured Stocks Comments Off

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Investment Considerations

  • Revenue-generating biosciences company focused on improving the delivery of bioactive compounds through gourmet foods
  • Proprietary technology shown to enhance the bioavailability of orally ingested cannabinoids while improving the taste
  • Actively developing and selling hemp oil-based gourmet food products through consumer brands ViPova™ and Lexaria Energy
  • Partnership with one of the world’s largest cigarette companies provides up to US$12 million in funding for clinical investigations conducted by Lexaria Nicotine LLC to explore oral forms of nicotine delivery using the Company’s patented DehydraTECH™ technology


Saturday, May 6th, 2017 Featured Stocks Comments Off

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek’s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Investment Considerations

  • Over C$140 million total equity funds raised to date from top tier strategic investors
  • Cannabis dispensaries in Nevada sold approximately $425 million of product, giving the state $70 million in taxes for the first full year of recreational adult-use sales
  • Organic growth of Green Growth Brands in Nevada includes 8 retail cannabis dispensary licenses to operate in the state and two cultivation facilities, positioning the company to be one of the largest vertically integrated operators in Nevada
  • At maturity, Nevada is seen as a consumer market representing $150 million to $250 million in revenue potential to Green Growth Brands as it builds to 10 or more dispensaries across multiple brand formats
  • North American expansion strategy involves easy-to-navigate experience that involves a surprise element – localized, authentic consumer experiences
  • Retail partners provide distribution opportunities in over 4,000 stores as well as through robust and established digital platforms
  • Pending acquisition of Just Healthy LLC provides Green Growth Brands with a license for up to three medical cannabis dispensaries in Northampton, Massachusetts, along with a cultivation and processing site, in a potential $60 million market


Saturday, May 6th, 2017 Featured Stocks Comments Off

Genprex Inc. (NASDAQ: (GNPX)

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Investment Considerations

  • Lung cancer is one of the most prevalent and deadly cancers worldwide. Genprex aims to develop cutting-edge gene therapies to improve outcomes, which have not changed significantly in the past 25 years despite radical advances in drug development and novel therapeutic standards.
  • Genprex holds a portfolio of 30 issued and two pending patents covering technologies and targeted molecular therapies, all exclusively licensed from University of Texas MD Anderson Cancer Center. Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who otherwise would not benefit from these important cancer therapies, or who have become resistant to them.
  • Genprex had a cash position of $10.3 million as of September 30, 2018.


Saturday, May 6th, 2017 Featured Stocks Comments Off

Canopy Rivers Inc. (TSX.V:RIV) (OTC: CNPOF)

Canopy Rivers Inc. (TSX.V:RIV) (OTC:CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED), NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Investment Considerations

  • Partnership with Canopy Growth leverages the network, expertise and innovation capabilities of the world’s largest cannabis company
  • Diversified portfolio of high-quality licensed cannabis producers, late-stage applicants, ancillary products and brands
  • Investments tailored to meet unique needs of each counterparty while achieving positive cash flow, secured downside protection and upside equity optionality
  • Access to an alternative investment vehicle characterized by early entry points, detailed counterparty due diligence and distinguished partners


Saturday, May 6th, 2017 Featured Stocks Comments Off

Millennial Lithium Corp. (TSX.V: ML) (FSE: A3N2) (OTC: MLNLF)

Millennial Lithium Corp. (TSX.V: ML) (FSE: A3N2) (OTC: MLNLF) is engaged in the development of the Pastos Grandes lithium project in Salta Province, Argentina. The company’s Pastos Grandes project totals approximately 10,000 hectares located in geopolitically stable, mining-friendly jurisdictions. The company also enjoys a solid strategic partnership with GCL, a Chinese solar giant that has become Millennial Lithium’s lead investor with approximately $30 million investment to date.

Millennial Lithium’s compelling valuation places it with a $123 million market cap, third only to Lithium Americas and Orocobre in the region. The company holds a strong cash position of C$40 million and is pursuing a strategic plan moving forward in 2019 that includes an updated NI 43-101 resource report and a full bankable feasibility study, including supporting evaporation ponds and pilot processing plant.

Projects

Argentina currently produces 17 percent of the world’s lithium supply. Lithium is at the cornerstone of a quiet industrial revolution as it brings together energy, automotive and technologies companies to foster a lasting move away from carbon-based resources. Lithium demand is expected to grow at an annual rate of 22 percent through 2025 with increased demands for lithium-ion batteries used in electric vehicles and battery-based energy storage leading the way.

Millennial Lithium has a world-class lithium brine asset strategically located in the heart of the Argentinean portion of the South American “Lithium Triangle.”

The company’s flagship lithium brine project, Pastos Grandes, is following a two-year timeline to production as a result of some of the best infrastructure in the Lithium Triangle. Located 231 km from the city of Salta at an elevation of 3,800 meters, Pastos Grandes is accessible year-round with all-weather access to paved highways, power and natural gas. Based on proven technology, brine extraction, solar evaporation and conventional lithium brine processing, Millennial Lithium’s preliminary economic assessment (PEA) of the Pastos Grandes project, completed by international engineering firm WorleyParsons, estimates a mine life of 25 years with a three-year ramp up to 25,000 tonnes per year of Lithium-Carbonate. A 3 tonne-per-month lithium carbonate pilot plant is currently being built for use at the site.

To date, 23 exploration wells are completed with $40 million spent in development. A revised Resource Estimate is planned for Q1 2019. Four pumping wells are also to be completed in Q1 2019 with two water wells currently being drilled in support of the ongoing Feasibility Study, also being completed by WorleyParsons. Infrastructure buildup is underway, including completion of a 40-man camp, hybrid solar-diesel power system, pilot plant and laboratory with ICP unit for rapid sample assays and a liming plant for treating concentrated brines form the pilot ponds. Millennial Lithium is also constructing a Pastos Grandes community center/warehouse and all-purpose building that is central to building community relations with local residents.

Encouraging results from an extended pumping test of a second production-scale well at the Pastos Grandes project revealed that at a pumping rate of 15 liters/second (L/s), the lithium content remained consistent over the 23-day trial period with a drawdown of approximately 57 meters with rapid recovery. Estimated transmissivity (the rate at which the brine moves through the aquifer) is 40 square meters per day, demonstrating the aquifer’s strong potential to sustain a long-term pumping rate of 15 L/s.

Brine sampling completed daily during the pumping test over the 23-day period revealed the chemistry is consistent with lithium ranging from 482 mg/L and 518 mg/L, averaging 495 mg/L. The best lithium values occurred during the last five days of the pumping test. The magnesium to lithium (Mg/Li) ratio averages 5.3 and the average potassium to lithium ratio (K/Li) is 10.5 and the average sulphate to lithium ratio (SO4/Li) is 16.4. Sampling was conducted in accordance with CIM guidelines for brine resource evaluation, with an appropriate chain of custody and QA/QC program in place for ensuring veracity, accuracy and precision of the analytical results.

Management Team

Millennial Lithium’s highly prospective lithium assets and strategies are bolstered by a world class management and board with extensive experience in lithium and large development projects.

President/CEO/Director Farhad Abasov, MBA, has founded and managed a number of mining aassets with successful exits in the last few years. He was president and CEO of Allana Potash which was sold to Israel Chemicals Ltd. for $170 million in 2015. As executive chairman of Rodinia Lithium, Abasov developed lithium bring projects in Argentina in 2016. He was also co-founder of Potash One, acquired by German potash company K+S for $430 million in 2010, and was senior vice president, strategy, at Energy Metals, acquired by Uranium One for $1.88 million in 2007.

Iain Scarr, BSc., MBA, is Chief Operating Officer with a wealth of experience in lithium brine development and operations. He worked at Rio Tinto, industrial minerals, including lithium resource development in Serbia. Scarr led feasibility work at Sal de Vida lithium brine project (Galaxy Resources, Argentina); completed the Rincon lithium brine project feasibility study (Enirgi, Argentina); and is a resident of Salta with established, strong relationships in the region.

Chief Financial Officer Max Missiouk, CPA, CMA, has served as a CFP and controller for a number of publicly listed resource and venture companies including Allana Potash Corp. and Crocodile Gold Corp. He is a CPA (CMA) and has a post-graduate degree in banking and finance management.

Peter J. MacLean, Ph.D., P.Geo, is senior vice president, technical services. He has more than 30 years of exploration and development experience in North America, South America and Africa. Most recently, MacLean acted as senior vice president/exploration of Allana Potash Corp. and directed all exploration and development activities on its flagship Danakhil Potash Project in Ethiopia including managing the company’s Feasibility Study and overseeing pilot solution mining and evaporation pond trials. He has also worked extensively on projects throughout the Americas and is fluent in Spanish.

Peter Ehren, M.Sc., AusIMM CP, process consultant, has been involved in lithium brines for more than 20 years. Ehren has worked at the Salar de Atacama as part of SQM’s team of leading evaporation technology experts, rising to the position of R&D manager. He has worked in the majority of lithium basins worldwide for numerous projects including Orocobre’s Salar de Olaroz Project.

Investment Considerations

  • Robust brine lithium resource with 2.1 million tonnes lithium-carbonate equivalent (LCE) of Measured and Indicated Resource and 878,000 tonnes LCE of Inferred Resource
  • Strong 43-101 Resource Estimate with an update expected in Q1 2019 with potential upside from newly acquired REMSA ground
  • Preliminary Economic Assessment (PEA) completed; mining and processing methods for lithium brines are proven; site is amenable to modular and scalable production
  • Strategically located with developed infrastructure in geopolitically stable environment
  • Located in Salta Province, Argentina, rated No. 1 Mining Jurisdiction by the Fraser Institute
  • World class management and board with solid strategic partnership with GCL, a Chinese solar giant investing $30 million in Millennial Lithium
  • Mine life of 25 years with three-year ramp up to 25,000 tonnes per year of lithium-carbonate
  • OPEX estimate of US$3,218/tonne of Li-Carb over the mine life
  • Global demand for lithium is expected to grow at an annual rate of 22% until 2025 with increased demand for lithium-ion batteries for use in electric vehicles and battery-based energy storage leading the way
  • Demand for lithium carbonate is expected to rise to more than 850,000 tonnes by 2025 from 225,000 tonnes in 2018, with larger spikes anticipated post-2025


Saturday, May 6th, 2017 Featured Stocks Comments Off

Cannabis Strategic Ventures, Inc. (OTC: NUGS)

Cannabis Strategic Ventures, Inc. (OTC: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Investment Considerations

  • U.S. cannabis market growing at an accelerated rate with industry analysts projecting a $50 billion marketplace by 2026
  • Investments into cannabis ventures expected to grow 1,308%, reaching $100 billion by 2029
  • Through subsidiaries like BudHire™, company is uniquely positioned to fully capitalize on burgeoning need for outsourced personnel solutions for the cannabis sector
  • Job postings within the cannabis industry increased by 445% in 2017, an explosive change from the 18% year-over-year cannabis jobs growth in 2016


Saturday, May 6th, 2017 Featured Stocks Comments Off